Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tricuspid Regurgitation clinical trials
13 of 18 indexed Tricuspid Regurgitation trials are currently recruiting.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 13 currently recruiting · #953 of 28,707 conditions by registered trial count
Tricuspid Regurgitation: 18 US clinical trials tracked, 13 recruiting.
Tricuspid Regurgitation is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. The most active sponsor is Edwards Lifesciences, running 3 of these trials.
Enrollment posture brief
Registry condition tricuspid-regurgitation
OPEN 13 | RECR 72% | LATE 0 | EARLY 0 | RANK #953 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cardiomyopathies (72% recruiting · 18 trials)
Tricuspid Regurgitation lists 13 open slots (72% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tricuspid Regurgitation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tricuspid Regurgitation is recruiting above its size-band peers.
13 of 18 indexed trials (72.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Tricuspid Regurgitation research.
Edwards Lifesciences accounts for 3 of 18 trials (16.7%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Tricuspid Regurgitation enrolment sits around 150 participants.
Median target enrolment is 150 among the 18 trials that report a genuine target (sentinel values excluded). 9 of those (50%) plan for fewer than 100 participants.
-
Tricuspid Regurgitation research is mostly interventional.
13 interventional and 5 observational studies make up this index (72.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
TriClip CED RWE Study
Abbott Medical Devices
NCT06920745
TTVR STRONG Under Coverage With Evidence Development (CED) Study
Edwards Lifesciences
NCT06833476
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Edwards Lifesciences
NCT04097145
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
Montefiore Medical Center
NCT06033274
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Abbott Medical Devices
NCT04761120
TTVR Early Feasibility Study
Medtronic Cardiovascular
NCT04433065
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
P+F Products + Features USA
NCT06137807
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
Laplace Interventional
NCT06183684
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
University of Washington
NCT02537769
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
VDyne
NCT05848284
Trisol System EFS Study
Trisol Medical
NCT04905017
EFS of the DUO System for Tricuspid Regurgitation
CroiValve Limited
NCT05913908
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
Innoventric
NCT06212193
TRILUMINATE Pivotal Trial
Abbott Medical Devices
NCT03904147
Clinical Study of Edwards Cardioband FIT Valve Repair System
Edwards Lifesciences
NCT03382457
Development of an Algorithm to Differentiate Heart Murmurs Using Electronic Stethoscopes
Eko Devices
NCT04400513
Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery
Icahn School of Medicine at Mount Sinai
NCT02675244
Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques
Mayo Clinic
NCT05006443
Phase Distribution
Phase data not available
Top Sponsors
Named interventions
Most-linked intervention names on Tricuspid Regurgitation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tricuspid Regurgitation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tricuspid Regurgitation page
18 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Tricuspid Regurgitation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Edwards Lifesciences sponsors the most Tricuspid Regurgitation trials on record, review their full trial history before evaluating a specific study. See Edwards Lifesciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tricuspid Regurgitation condition card totals 18 registered trials; most-linked intervention Transcatheter Tricuspid Valve Replacement; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.